Your browser doesn't support javascript.
loading
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Miki, Ikuya; Nakamura, Tsutomu; Kuwahara, Akiko; Yamamori, Motohiro; Nishiguchi, Kohshi; Tamura, Takao; Okuno, Tatsuya; Omatsu, Hideaki; Mizuno, Shigeto; Hirai, Midori; Azuma, Takeshi; Sakaeda, Toshiyuki.
Affiliation
  • Miki I; Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
Int J Med Sci ; 9(9): 748-56, 2012.
Article in En | MEDLINE | ID: mdl-23136537
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Polymorphism, Single Nucleotide / Thyroid Hormone Receptors beta / Chemoradiotherapy Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2012 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Polymorphism, Single Nucleotide / Thyroid Hormone Receptors beta / Chemoradiotherapy Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2012 Type: Article